Dexcom’s Latest Stelo Glucose Biosensor System Receives FDA Clearance for Over-the-Counter Use
Dexcom a leader in continuous glucose monitoring (CGM) technology, has achieved a significant milestone with the clearance of its new over-the-counter (OTC) continuous glucose monitor named Stelo by the U.S. Food and Drug Administration (FDA). This approval marks a pivotal moment in diabetes management, offering increased accessibility and convenience for individuals seeking real-time glucose monitoring solutions. Continuous glucose monitors, such as Dexcom’s Stelo , are compact sensors that penetrate the skin to provide continuous tracking of glucose levels. These devices play a crucial role in diabetes management by wirelessly transmitting data to smartphones, enabling users, their families, and healthcare providers to monitor glucose levels and respond promptly to potential emergencies. What sets Stelo apart is its accessibility without the need for a prescription, making it the first OTC glucose biosensor approved by the FDA. This groundbreaking feature opens doors for indivi...